Quarterly Report – Period To 31 March 2024

8 April 2024
Posted in Video
8 April 2024 Orthocell

Orthocell has today published its Quarterly Report for the period ended 31 March 2024.

Highlights for this Quarter include:

● Increasing revenue driven by growth in new product sales. Year to date revenue of $4.88 million is up 40.7% from $3.47 million for the same period last year.
● Successful completion of a $3.5 million strategic placement
● Strong balance sheet with $20.1m cash at bank at the end of the quarter
● Strengthening the Board with appointment of the Hon Kim Beazley AC
● Successful completion of all nerve repair surgeries in Remplir™ US market authorisation study
● Submission of Singapore Regulatory Application for Remplir™ in February 2024

Orthocell Managing Director, Paul Anderson, said:

“Orthocell has completed a very solid quarter, growing revenues whilst strengthening the balance sheet and share register. I am very pleased with the performance of our distribution partners and the continued increase in product adoption. With a highly respected and experienced Board now in place, we are in a strong position to continue to gain commercial traction and drive Remplir, our breakthrough nerve repair device, into global markets.”

Click here to read today’s ASX release.